Giampiero Valenzano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giampiero Valenzano has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah O. Khan
MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK
1 shared publication - Adam J. Mead
Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine and National Institute of Health Research, Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
1 shared publication - Benjamin Schuster-Böckler
Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publication - Bethan Psaila
MRC Weatherall Institute of Molecular Medicine University of Oxford Oxford UK
1 shared publication - Camelia Benlabiod
MRC Weatherall Institute of Molecular Medicine and National Institute of Health Research (NIHR) Biomedical Research Centre Cancer Theme, University of Oxford, OX3 9DS Oxford, UK
1 shared publication - Christina Simoglou Karali
MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine and National Institute of Health Research (NIHR), Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 14 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6761) , eadp3971
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA
Platelets are anucleate blood cells vital for hemostasis and immunity. During cell death and aberrant mitosis, nucleated cells release DNA, resulting in “cell-free” DNA in plasma (cfDNA). An excess of cfDNA is deleterious. Given their ability to internalize pathogen-derived nucleic acids, we hypothesized that platelets may also clear endogenous cfDNA. We found that, despite lacking a nucleus, platelets contained a repertoire of DNA fragments mapping across the nuclear genome. We detected fetal DNA in maternal platelets and cancer-derived DNA in platelets from patients with premalignant and cancerous lesions. As current liquid biopsy approaches utilize platelet-depleted plasma, important genetic information contained within platelets is being missed. This study establishes a physiological role for platelets that has not previously been highlighted, with broad translational relevance.
- 14 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6761) , eadp3971
Top Cited PapersOpen AccessPlatelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA
Platelets are anucleate blood cells vital for hemostasis and immunity. During cell death and aberrant mitosis, nucleated cells release DNA, resulting in “cell-free” DNA in plasma (cfDNA). An excess of cfDNA is deleterious. Given their ability to internalize pathogen-derived nucleic acids, we hypothesized that platelets may also clear endogenous cfDNA. We found that, despite lacking a nucleus, platelets contained a repertoire of DNA fragments mapping across the nuclear genome. We detected fetal DNA in maternal platelets and cancer-derived DNA in platelets from patients with premalignant and cancerous lesions. As current liquid biopsy approaches utilize platelet-depleted plasma, important genetic information contained within platelets is being missed. This study establishes a physiological role for platelets that has not previously been highlighted, with broad translational relevance.
- Open Access
- 21 October 2024
- Published by Wiley in Current Protocols
- Vol. 4 (10) , e70032
Using Spectral Flow Cytometry to Characterize Anti‐Tumor Immunity in Orthotopic and Subcutaneous Mouse Models of Cancer
Mouse models remain at the forefront of immuno‐oncology research, providing invaluable insights into the complex interactions between the immune system and developing tumors. While several flow cytometry panels have been developed to study cancer immunity in mice, most are limited in their capacity to address the complexity of anti‐cancer immune responses. For example, many of the panels developed to date focus on a restricted number of leukocyte populations (T cells or antigen‐presenting cells), failing to include the multitude of other subsets that participate in anti‐cancer immunity. In addition, these panels were developed using blood or splenic leukocytes. While the immune composition of the blood or spleen can provide information on systemic immune responses to cancer, it is in the tumor microenvironment (TME) that local immunity takes place. Therefore, we optimized this spectral flow cytometry panel to identify the chief cell types that take part in cancer immunity using immune cells from cancer tissue. We used pancreatic tumors implanted both orthotopically and subcutaneously to demonstrate the panel's flexibility and suitability in diverse mouse models. The panel was also validated in peripheral immune districts (the blood, spleen, and liver of tumor‐bearing mice) to allow comparisons between local and systemic anti‐tumor immunity. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Tumor induction—OrthotopicAlternate Protocol: Tumor induction—SubcutaneousBasic Protocol 2: Preparation of single‐cell suspensions from the tumor, spleen, liver, and blood of tumor‐bearing miceBasic Protocol 3: Staining single‐cell suspensions from the tumor, spleen, liver, and blood of tumor‐bearing mice
- 21 October 2024
- Published by Wiley in Current Protocols
- Vol. 4 (10) , e70032
Open AccessUsing Spectral Flow Cytometry to Characterize Anti‐Tumor Immunity in Orthotopic and Subcutaneous Mouse Models of Cancer
Mouse models remain at the forefront of immuno‐oncology research, providing invaluable insights into the complex interactions between the immune system and developing tumors. While several flow cytometry panels have been developed to study cancer immunity in mice, most are limited in their capacity to address the complexity of anti‐cancer immune responses. For example, many of the panels developed to date focus on a restricted number of leukocyte populations (T cells or antigen‐presenting cells), failing to include the multitude of other subsets that participate in anti‐cancer immunity. In addition, these panels were developed using blood or splenic leukocytes. While the immune composition of the blood or spleen can provide information on systemic immune responses to cancer, it is in the tumor microenvironment (TME) that local immunity takes place. Therefore, we optimized this spectral flow cytometry panel to identify the chief cell types that take part in cancer immunity using immune cells from cancer tissue. We used pancreatic tumors implanted both orthotopically and subcutaneously to demonstrate the panel's flexibility and suitability in diverse mouse models. The panel was also validated in peripheral immune districts (the blood, spleen, and liver of tumor‐bearing mice) to allow comparisons between local and systemic anti‐tumor immunity. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Tumor induction—OrthotopicAlternate Protocol: Tumor induction—SubcutaneousBasic Protocol 2: Preparation of single‐cell suspensions from the tumor, spleen, liver, and blood of tumor‐bearing miceBasic Protocol 3: Staining single‐cell suspensions from the tumor, spleen, liver, and blood of tumor‐bearing mice